X

Drug Profile

Aciclovir topical formulation - Yissum

Alternative Names: Acyclovir-topical formulation; P-0964a

Latest Information Update: 17 Apr 2007

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Yissum Research Development Company
Class
Mechanism of Action DNA-directed DNA polymerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Herpes simplex virus infections

Most Recent Events

17 Apr 2006 Discontinued - Clinical-Phase-Unknown for Herpes simplex virus infections in Israel (Topical)
05 Oct 2001 Investigation in Herpes simplex virus infections in Israel (Topical)
03 Oct 2001 New profile

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com